中华预防医学杂志
中華預防醫學雜誌
중화예방의학잡지
CHINESE JOURNAL OF
2009年
4期
277-281
,共5页
汪永忠%李燕%蒋成芹%郑敏%章永%熊玉华%杨育燕%罗开敏
汪永忠%李燕%蔣成芹%鄭敏%章永%熊玉華%楊育燕%囉開敏
왕영충%리연%장성근%정민%장영%웅옥화%양육연%라개민
获得性免疫缺陷综合征%抗病毒药,治疗%规范
穫得性免疫缺陷綜閤徵%抗病毒藥,治療%規範
획득성면역결함종합정%항병독약,치료%규범
Acquired immunodeficiency syndrome%Antiviral agents,therapy%Benchmarking
目的 了解艾滋病母婴传播阻断抗病毒治疗的规范用药水平,探索其影响因素,为制定规范用药的措施提供依据.方法 采用现况调查方法在云南省5个艾滋病高、中流行县(市、区)对2005年1月至2007年6月接受母婴传播阻断服务的167例孕产妇及57名提供服务的医务人员进行调查,对艾滋病母婴传播阻断抗病毒治疗方案的选择与应用是否合理及艾滋病病毒(HIV)感染孕产妇依从性的主要影响因素进行定性和定量调查.结果 接受母婴传播阻断服务的167例HIV感染产妇中,抗病毒治疗规范用药率为65.87%(110/167);其中方案选择合理率为88.02%(147/167),产时用药合理率81.37%(131/161),依从率为87.42%(146/167).艾滋病母婴传播阻断抗病毒治疗规范用药的主要影响因素为确诊时间(OR=2.617;95%CI: 1.184~5.783),是否在阻断定点机构分娩(OR=0.064;95%CI:0.007~0.607),民族(OR=0.344;95%CI:0.162~0.730),是否知道服药阻断的目的 (OR=6.843;95%CI:1.449~32.312),以及医生对抗病毒治疗的认识不够,5个关键知识点(母婴阻断目的 、不按要求服药后果、各方案疗效、CD4高低与选择方案的关系、有关药物可能出现的副作用)的正确认识率为47.72%(136/285).结论 艾滋病母婴传播阻断抗病毒治疗规范用药的总体水平不高,受医患双方及社会等多种因素影响,有必要针对主要影响因素制定规范用药的措施.
目的 瞭解艾滋病母嬰傳播阻斷抗病毒治療的規範用藥水平,探索其影響因素,為製定規範用藥的措施提供依據.方法 採用現況調查方法在雲南省5箇艾滋病高、中流行縣(市、區)對2005年1月至2007年6月接受母嬰傳播阻斷服務的167例孕產婦及57名提供服務的醫務人員進行調查,對艾滋病母嬰傳播阻斷抗病毒治療方案的選擇與應用是否閤理及艾滋病病毒(HIV)感染孕產婦依從性的主要影響因素進行定性和定量調查.結果 接受母嬰傳播阻斷服務的167例HIV感染產婦中,抗病毒治療規範用藥率為65.87%(110/167);其中方案選擇閤理率為88.02%(147/167),產時用藥閤理率81.37%(131/161),依從率為87.42%(146/167).艾滋病母嬰傳播阻斷抗病毒治療規範用藥的主要影響因素為確診時間(OR=2.617;95%CI: 1.184~5.783),是否在阻斷定點機構分娩(OR=0.064;95%CI:0.007~0.607),民族(OR=0.344;95%CI:0.162~0.730),是否知道服藥阻斷的目的 (OR=6.843;95%CI:1.449~32.312),以及醫生對抗病毒治療的認識不夠,5箇關鍵知識點(母嬰阻斷目的 、不按要求服藥後果、各方案療效、CD4高低與選擇方案的關繫、有關藥物可能齣現的副作用)的正確認識率為47.72%(136/285).結論 艾滋病母嬰傳播阻斷抗病毒治療規範用藥的總體水平不高,受醫患雙方及社會等多種因素影響,有必要針對主要影響因素製定規範用藥的措施.
목적 료해애자병모영전파조단항병독치료적규범용약수평,탐색기영향인소,위제정규범용약적조시제공의거.방법 채용현황조사방법재운남성5개애자병고、중류행현(시、구)대2005년1월지2007년6월접수모영전파조단복무적167례잉산부급57명제공복무적의무인원진행조사,대애자병모영전파조단항병독치료방안적선택여응용시부합리급애자병병독(HIV)감염잉산부의종성적주요영향인소진행정성화정량조사.결과 접수모영전파조단복무적167례HIV감염산부중,항병독치료규범용약솔위65.87%(110/167);기중방안선택합리솔위88.02%(147/167),산시용약합리솔81.37%(131/161),의종솔위87.42%(146/167).애자병모영전파조단항병독치료규범용약적주요영향인소위학진시간(OR=2.617;95%CI: 1.184~5.783),시부재조단정점궤구분면(OR=0.064;95%CI:0.007~0.607),민족(OR=0.344;95%CI:0.162~0.730),시부지도복약조단적목적 (OR=6.843;95%CI:1.449~32.312),이급의생대항병독치료적인식불구,5개관건지식점(모영조단목적 、불안요구복약후과、각방안료효、CD4고저여선택방안적관계、유관약물가능출현적부작용)적정학인식솔위47.72%(136/285).결론 애자병모영전파조단항병독치료규범용약적총체수평불고,수의환쌍방급사회등다충인소영향,유필요침대주요영향인소제정규범용약적조시.
Objective To understand the status of standard medication of antiretroviral therapy and identify its correlationship with preventing mother-to-child transmission of HIV (PMTCT). Methods Qualitative and quantitative methods for measuring of standard medication towards antiretroviral therapy of PMTCT were used in a cross-sectional study of 167 pregnant women who had accessed to PMTCT services and 57 physicians providing service from January 2005 to June 2007 in 5 HIV epidemic counties in Yunnan province. Results A total of 167 mothers were recruited, of which 65. 87% (110/167) demonstrated for standard medication. The percentage of rational seloction of antivirus-therapy regimen was 88.02% (147/ 167). HIV positive mothers with rational using medicine during labor covered 81.37% (131/161). 87.42% (146/167)of women demonstrated good compliance. The main correlations with the standard medication level of HIV positive pregnant women and their infants were as follows: diagnose time(OR=2.617;95% CI: 1.184-5.783), place of delivery (OR=0.064; 95% CI: 0.007-0.607), minorities (OR = 0. 344; 95% CI:0.162 - 0.730), understanding of HIV women for antiretroviral therapy (OR=6.843; 95% CI: 1.449-32.312) ,and doctors' cognition about the regimen for antiretroviral therapy was not enough; 5 key knowledge points (purpose of PMTCT, the consequence of not requiring standard medication, the effect of knowing regimens, the relationship of CD4 levels and selected regimens, the side effect of the relevant medicine) score rate was 47.72% (136/285). Conclusion The proportions of standard medication in Corresponding author: LI Yan, Email: yanli20021965@21cn.comPMTCT antiretroviral therapy were not high. Standard medication might be associated with multiple factors from doctors, patients and society. It is necessary to make some steps to improve standard medication of antiretroviral therapy in PMTCT.